W
Windward Bio
Ultra-long-acting antibodies for respiratory and skin diseases
About Windward Bio
Windward Bio is a clinical-stage biotechnology company based in Basel, Switzerland, developing ultra-long-acting antibody medicines for people with serious respiratory and dermatologic immunological diseases. Its approach is to in-license clinical-stage antibodies against validated targets and extend their dosing intervals, aiming to cut the treatment burden of frequent injections in chronic conditions such as asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis. The lead candidate, WIN378, is a long-acting anti-TSLP monoclonal antibody licensed from Kelun-Biotech and Harbour BioMed; it is being evaluated with twice-yearly dosing in the Phase 2/3 POLARIS programme in asthma, with COPD as a further indication. The second programme, WIN027, licensed from Qyuns Therapeutics, is a long-acting bispecific antibody that blocks both TSLP and IL-13 and is being developed for respiratory and dermatology indications. Windward Bio's common shares trade on the Nasdaq Global Select Market under the symbol WWB.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 11
- Open positions
- 1
- Dealroom signal
- 95.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Oncology, Immune System, Rumoured $1B, Biotech and Pharma, Rare Diseases, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | May 2026 | $165M | $660M | Sanofi · SR One · RTW Investments · RA Capital Management | ↗ |
| SERIES AOther financing | Jan 2025 | $200M | $800M | Omega Funds · RTW Investments · Quan Capital · Pivotal BioVenture Partners | ↗ |
Growth signals
Latest recorded traffic for Windward Bio is 2.5K monthly website visits, up 25% over the last three months. Windward Bio's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Windward Bio in the Basel ecosystem
The Windward Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Novo Holdings
OrbiMed
Blue Owl CapitalOmega Funds
RTW Investments
Quan Capital
Pivotal BioVenture PartnersSR One
Qiming Venture Partners
Series B and later4 investors entered at this stage
Sanofi
RA Capital ManagementJanus Henderson Investors
Harbour BioMed
Source: Dealroom Talent Intelligence.
See Windward Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










